Champions Oncology (CSBR) Non-Current Assets (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Non-Current Assets of $7.8 million for Q2 2026, down 22.19% year-over-year from $10.0 million in Q2 2025, and down 5.95% quarter-over-quarter from $8.3 million in Q1 2026.
Champions Oncology (CSBR) Non-Current Assets (2011 - 2026) Analysis & Trends
Champions Oncology's Non-Current Assets history runs 16 years deep, the most recent figure standing at $7.8 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 22.19% year-over-year to $7.8 million; the TTM figure through Apr 2026 stood at $34.4 million (down 21.52% YoY), while the FY2026 annual figure was $7.8 million, down 22.19% from the prior year.
- Non-Current Assets for Q2 2026 stood at $7.8 million, down from $8.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $16.0 million in Q3 2022, with the low at $7.8 million in Q2 2026.
- The 5-year median for Non-Current Assets is $13.0 million (2024), against an average of $12.6 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 39.57% in 2022, then retreated 24.41% in 2026.
- Champions Oncology's Non-Current Assets stood at $15.8 million in 2022, then dropped by 9.39% to $14.3 million in 2023, then retreated by 21.86% to $11.2 million in 2024, then fell by 20.85% to $8.8 million in 2025, then fell by 12.0% to $7.8 million in 2026.
- Business Quant data shows CSBR's Non-Current Assets at $7.8 million in Q2 2026, $8.3 million in Q1 2026, and $8.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 7.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 7.77 Mn |
| Jan 31, 2026 | 8.26 Mn |
| Oct 31, 2025 | 8.83 Mn |
| Jul 31, 2025 | 9.53 Mn |
| Apr 30, 2025 | 9.99 Mn |
| Jan 31, 2025 | 10.93 Mn |
| Oct 31, 2024 | 11.16 Mn |
| Jul 31, 2024 | 11.76 Mn |
| Apr 30, 2024 | 12.49 Mn |
| Jan 31, 2024 | 13.59 Mn |
| Oct 31, 2023 | 14.28 Mn |
| Jul 31, 2023 | 14.98 Mn |
| Apr 30, 2023 | 14.85 Mn |
| Jan 31, 2023 | 15.79 Mn |
| Oct 31, 2022 | 15.76 Mn |
| Jul 31, 2022 | 16.02 Mn |
| Apr 30, 2022 | 15.71 Mn |
| Jan 31, 2022 | 15.76 Mn |
| Oct 31, 2021 | 15.59 Mn |
| Jul 31, 2021 | 15.51 Mn |